Boehringer Ingelheim

Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in Research and Development, the company focuses on developing innovative therapies in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. More than 53,500 employees serve over 130 markets to build a healthier, more sustainable, and equitable tomorrow. Learn more at www.boehringer-ingelheim.com.

Boehringer Ingelheim, Taiwan has served in Taiwan since 1975 as a healthy issue solution provider with more than 350 employees and 3 different offices located in north, central and south Taiwan. With core business in Human Pharm and Animal Health, we support patients in the area of the respiratory, oncology, diabetes, cardiovascular, stroke, Parkinson's disease, fibrosis disease and more. We support companion animals and their owners in parasite prevention and the treatment for heart disease and chronic kidney disease, also support livestock farmer in serval disease prevention, such as porcine reproductive and respiratory syndrome, Newcastle Disease and more.

More information about Boehringer Ingelheim:
www.boehringer-ingelheim.com (Corporate Website)
www.boehringer-ingelheim.com/tw (Taiwan Website)
www.facebook.com/1985BITW (Social Innovation Facebook Page)
http://annualreport.boehringer-ingelheim.com (2023 Annual Report)
https://line.me/R/ti/p/%40lxh2761d (LINE@ Official account)
https://bit.ly/3Ux6p8B  (Media Map)

https://bit.ly/4d3M1To (Sustainable Development - For Generations)

* To be used from April 16, 2024 until the Annual Results Press Conference in 2025